Purchase Order 75N91024P00196
- Not listed
- The National Cancer Institute within the National Institutes of Health awarded a $589,617.13 firm fixed-price purchase order to Illumina, Inc. on September 1, 2021, for maintenance services supporting genomic sequencing equipment at its Bethesda, Maryland facility. The contract covers preventative maintenance and emergency support for seven Illumina sequencers and associated instrumentation used by the NCI's Genetics Branch to advance cancer research and genomic analysis capabilities. This award...
- The National Cancer Institute awarded a $93,351.36 firm fixed-price purchase order to Illumina, Inc. on April 1, 2026, for a two-year maintenance agreement covering two NextSeq 2000 sequencers located at the agency's Bethesda, Maryland facility. The contract, which extends through March 31, 2027, represents a standard service and support engagement for Illumina's widely-deployed genetic sequencing instruments across the federal research enterprise. No set-aside designation was applied to this...
- The National Cancer Institute (NCI) within the National Institutes of Health (NIH) awarded a $205,376.00 firm fixed price purchase order to Illumina, Inc. for maintenance services for a government-owned Illumina NextSeq 2000 sequencing system. The base period runs from February 1, 2024 through January 31, 2028, with the potential for three one-year extensions. The contract provides for annual preventative maintenance, remote technical support, and on-site emergency repairs within two business...
- This firm fixed-price purchase order contract was awarded by the National Cancer Institute (NCI), a component of the National Institutes of Health (NIH), to Illumina, Inc. for maintenance services on a government-owned Illumina NovaSeq 6000 sequencing instrument. The $134,247.36 contract provides annual preventive maintenance, emergency repair, software/firmware updates, replacement parts, and technical support for the sequencing system located at the NCI's Laboratory of Pathology in Bethesda,...
- The National Cancer Institute (NCI), a component of the National Institutes of Health under the Department of Health and Human Services, awarded a $67,824 firm fixed-price purchase order to Illumina, Inc. for preventive maintenance, emergency service, support, and coverage of a government-owned Illumina NovaSeq 6000 sequencing system located at the NCI's Center for Cancer Research facility in San Diego, California. The contract, awarded on May 1, 2021, with a completion date of April 30, 2022,...
- The National Cancer Institute (NCI) awarded a $116,652 firm fixed-price purchase order to Illumina, Inc. for preventative maintenance services on an Illumina NextSeq 550 sequencer. The contract was awarded without a set-aside and covers an initial base period from 8/21/2020 to 8/20/2021, with a total performance period through 5/7/2025. Illumina is the original equipment manufacturer (OEM) and the only known provider of these specialized maintenance services. The contract supports the NCI's...
- The Department of Health and Human Services, National Institutes of Health, National Cancer Institute awarded a $130,847 firm fixed price purchase order to Illumina, Inc. of San Diego, California. The purpose is to procure preventive maintenance services for a government-owned Illumina NovaSeq 6000 Sequencing System located at the National Cancer Institute in Bethesda, Maryland. The Laboratory of Pathology requires these services to maintain optimal instrument operation, generate comparable...
- This firm fixed-price purchase order was awarded by the Department of Health and Human Services' National Institutes of Health National Cancer Institute to Illumina, Inc., a manufacturer of genetic sequencing systems and solutions, for preventive maintenance, emergency service, and support for a government-owned Illumina NovaSeq 6000 Sequencing System. The contract has a period of performance from August 1, 2022 to July 31, 2023 and a potential value of $119,523.28. The requirement was...
- The Department of Health and Human Services National Institutes of Health National Cancer Institute awarded a firm fixed price purchase order contract valued at $300,280.00 to Illumina, Inc. for maintenance services on Illumina NextSeq 500 genomic sequencing equipment. The contract has a completion date of May 18, 2023 and was awarded on May 19, 2018. Illumina, a for-profit manufacturer of genomic analysis instruments and reagents, has been awarded numerous prime and subcontract federal awards...
- The Department of Health and Human Services National Institutes of Health National Cancer Institute awarded a firm fixed price purchase order contract to Illumina, Inc. for maintenance services on the agency's Illumina MiSeq and NextSeq gene sequencing instruments. The contract has a potential value of $240,423.72 and covers a 12-month base period from May 13, 2019 to May 12, 2020, with four 12-month option periods. The contract provides for preventive maintenance inspections, replacement parts,...
The National Cancer Institute awarded a $735,959 firm fixed-price purchase order to Illumina, Inc. on March 18, 2024, for preventive maintenance and emergency repair services supporting a government-owned Illumina NovaSeq 6000 sequencing system at the National Institutes of Health Clinical Center in Bethesda, Maryland. The contract encompasses a one-year base period (March 2024 through March 2025) and includes four one-year option periods, extending through March 2029. Services include annual preventive maintenance inspections, unlimited remote technical support, on-site emergency repairs, software updates, and replacement parts necessary to maintain operational continuity of the specialized genomic sequencing equipment used by the Surgery Branch within the National Cancer Institute's Center for Cancer Research. As the original equipment manufacturer, Illumina qualifies as the sole source for internal components, software, and maintenance services for the NovaSeq 6000 system, eliminating the need for competitive procurement or set-aside designations. The contract structure with quarterly payments made in arrears reflects the critical nature of this equipment to the agency's genomic research operations supporting cancer diagnostics and research initiatives. This award builds on Illumina's extensive federal contracting history, which includes substantial genomic sequencing support across multiple agencies and a significant $45 million Indefinite Delivery contract vehicle with the U.S. Department of Agriculture.
Name | Description | Solicitation Number | FederalAgency | Type | PostedDate |
|---|---|---|---|---|---|
NOTICE OF INTENT TO SOLE SOURCE: Illumina NovaSeq 6000 Maintenance | 75N91024Q00019 | Department of Health and Human Services National Institutes of Health National Cancer Institute | Pre-Solicitation 1/1 | 12/7/23, 5:11 PM |
Mod # | Description | ReasonForModification | Federal Obligation | Date |
|---|---|---|---|---|
| P00002 | Exercise an Option | $147.0k | 3/9/26 | |
| P00001 | Exercise an Option | $141.3k | 3/10/25 | |
| Not listed | Not listed | $135.9k | 3/13/24 |